Navigation Links
Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.

Ontario biotech companies work together on innovative bone protein


TORONTO, Oct. 28 /PRNewswire/ - Thomas Wellner, President and CEO of Therapure BioPharma Inc. and Dr. Cameron Clokie, President and CEO of Induce Biologics Inc. today announced a development partnership utilizing an innovative approach to the production and manufacture of selected growth factors for stimulating bone regeneration. Such growth factors are critical tools used in regenerative medicine, with particular applications in the regeneration of the skeleton.

Therapure will apply its experience and knowledge in cell culture and in the design and development of scaled-up biologic manufacturing processes to advance the initial research and development conducted by Induce. The technology is a result of over 10 years of research and development by the founders of Induce in the areas of bone regeneration and the development of growth factor containing bone grafts.

"Induce's technology is a tremendous example of the creativity and innovation that exists in Ontario," said Thomas Wellner. "We are very pleased that they have chosen Therapure Biopharma as their partner for the further development of this important new technology and we look forward to working with them to bring this product to a global market."

"Our technology was invented in Canada", said Cameron Clokie, "and we are excited to have found a company in Ontario that is capable of working with us to further develop this technology. We are pleased that Therapure Biopharma is as eager as we are to make this technology available to patients world-wide."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit:

About Induce Biologics Inc.:

Induce Biologics Inc was founded in 2008 to develop and commercialize technologies invented at the University of Toronto. Induce Biologics' goal is to utilize these technologies along with others being developed internally to create cost effective growth factor containing bone grafts for mammalian skeletal regeneration.

SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. opens for business with first client contracts
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
4. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
5. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
6. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
9. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
10. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
11. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia ... be hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” ... pathology adoption best practices and how Proscia improves lab economics and realizes an ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):